discriminate advanced (F3-F4) fibrosis was evaluated using AUROCs with 5-fold cross-validation repeated 100x. Optimal thresholds for F3-F4 fibrosis were selected based on the literature. Data presented are from an interim analysis on 1 May 2018.

**Results** A total of 4467 patients (median age 58 years, 55% women, 72% Caucasian, 59% with diabetes) were screened. In the 3220 with evaluable histology, median biopsy length was 2.0 cm, 8% F0, 9% F1, 13% F2, 31% F3, 40% F4, 59% with NAS ≥5. Median values of NFS, FIB-4, ELF, and LS by TE increased with worsening fibrosis (-0.96/2.19/9.21/8.8 kPa in F0-F2 vs 0.34/2.2/10.39/16.5 kPa in F3-F4 respectively). AUROCs ranged from 0.75 to 0.80 to discriminate advanced fibrosis (table 1). When tests were combined, performance characteristics improved and PPVs >98% were possible.

**Conclusions** In these large, global phase 3 trials of SEL, routinely available NITs demonstrated acceptable diagnostic performance for the discrimination of advanced fibrosis due to NASH.

---

**SOFOSBUVIR/VELPATASVIR IS EFFECTIVE AND SAFE IN PATIENTS WITH CONCOMITANT PROTON PUMP INHIBITOR USE IN CLINICAL STUDIES**

**Background** Prior to the availability of Phase 1 drug interaction data, concomitant proton pump inhibitor (PPI) use was prohibited in clinical trials of sofosbuvir/velpatasvir (SOF/VEL). Later clinical studies allowed for the use of up to 20 mg omeprazole or equivalent dosing. This analysis evaluated the efficacy and safety of patients with and without compensated cirrhosis who received SOF/VEL for 12 weeks and reported concomitant use of a PPI.

**Methods** This was a retrospective analysis from 12 Phase 2 and Phase 3 clinical studies in which patients of all genotypes with and without compensated cirrhosis received SOF/VEL for 12 weeks and reported concomitant use of a PPI. Efficacy was assessed by SVR12 and relapse rates and safety was assessed by treatment-emergent adverse events (AEs).

**Results** 87 patients reported concomitant use of a PPI. The mean age (range) was 57 years (26–78), 79% were male and 75% white; 56% of patients were infected with genotype 3 and 29% with genotype 1; 37% of patients had compensated cirrhosis and 39% were treatment experienced. The most common PPI was omeprazole reported by 68% of patients. The SVR12 rate was 97% (84 of 87 patients). Of the 3 patients who did not achieve SVR12, 2 patients relapsed (relapse rate 2%) and one patient with a history of diabetes discontinued SOF/VEL after 7 days of dosing due to hyperglycemia. No other patient had an AE which led to discontinuation or interruption of SOF/VEL. 78% of patients had an AE, most of which were mild, and 11% had a serious AE. These efficacy and safety are comparable to patients enrolled in the same studies who received SOF/VEL for 12 weeks without concomitant use of a PPI (SVR12 rate 97% [2445 of 2517 patients]; relapse rate 2% [40 of 2488 patients]).

**Conclusions** In Phase 2 and Phase 3 clinical studies, the single-tablet regimen of SOF/VEL for 12 weeks was effective and safe in patients with concomitant PPI use. These data support the use of SOF/VEL according to labeled recommendations with respect to co-administration of PPIs and other acid reducing agents.

---

**PHARMACOKINETICS OF ONCE-DAILY SOFOSBUVIR OR LEDIPASVIR/SOFOSBUVIR IN HCV-INFECTED PEDIATRICS AGED 3 TO 12 YEARS**

**Background** SOF 400 mg and LDV/SOF 90/400 mg are approved HCV treatment in adults and adolescents. Pharmacokinetic (PK) data indicates that SOF 200 mg and LDV/SOF 45/200 mg are appropriate doses in children 6 to <12 years old (y). SOF and LDV/SOF oral granules were developed; PK was assessed in children 3 to < 6 y.

**Methods** HCV-infected children (3 to <6 y) received SOF or LDV/SOF with doses selected to target exposures similar to adults: subjects ≥17 kg received SOF 200 mg or LDV/SOF 45/200 mg; subjects <17 kg received SOF 150 mg or LDV/SOF 33.75/150 mg, QD. Subjects received SOF+RBV 12 or 24 weeks (GT2 or GT3, respectively) or LDV/SOF 12 weeks (GT1, 4). Intensive PK sampling (IPK lead-in) was performed on Day 7 (SOF; N=11) or 10 (LDV/SOF; N=15). Exposures (AUCtau and Cmax) from subjects were compared to exposures in Phase 2/3 adult clinical programs. The primary endpoint was AUCtau of GS-331007 and LDV with predefined PK equivalence bounds of 50–200%.

**Results** All but 1 subject completed IPK assessments. At baseline, median age and weight for subjects was 5 y and 17 kg in SOF+RBV PK lead-in (N=11) and 5 y and 20 kg in LDV/SOF subjects (N=14). The predefined PK criteria were met as GS-331007 and LDV AUCtau were within the 50–200% boundaries as compared with the adult Phase 2/3 population (table 1). The GS-331007 Cmax (SOF+RBV) was modestly higher; these increases are not considered clinically relevant based on established exposure-safety analyses. SOF concentrations were within the range of those observed in the SOF and LDV/SOF adult Phase 2/3 population (data not shown).
Conclusions SOF 200 or 150 mg or LDV/SOF 45/200 or 33.75/150 mg, for subjects ≥17 kg or <17 kg, respectively, were well tolerated and provided similar exposures to those observed in adults. These data support the ongoing evaluation of these doses in children 3 to < 6 y.

**IDDF2019-ABS-0136**

**SOFOSBUVIR/VELPATASVIR FOR 12 WEEKS IS SAFE AND EFFECTIVE IN PATIENTS UNDERGOING DIALYSIS**

1Sergio Borgia*, 2Janet Dearden, 3Yooav Lurie, 4Stephen Shafar, 5Ashley Brown, 6Robert Hyland, 7Sophia Lu, 8Svetlana Markova, 9Hasadas Dvory-Szabol, 10Anu Osinusi, 11Christina Sze Man Yip, 12Eric Yoshida, 13Jose Luis Calleja, 14Edward Gane, 15GS-US-342-1003 Investigator. 1William Osler Health System, ON, Canada; 2Saint Barnabas Hospital, NY, USA; 3Department of Medicine, University of Alberta, AB, Canada; 4Imperial College Healthcare NHS Trust, UK; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Gordon and Leslie Diamond Health Care Centre, BC, Canada; 7Hospital Universitario Puerta De Hierro, Spain; 8Auckland City Hospital, New Zealand

10.1136/gutjnl-2019-IDDFabstracts.270

Background Approved HCV treatments for patients on dialysis are associated with complexities including drug-drug interactions, baseline resistance testing and use of ribavirin. Despite higher concentrations of the primary circulating sofosbuvir (SOF) metabolite, GS-331007, in severe renal impairment, real-world cases demonstrated substantial use of SOF-based regimens in this population without safety concerns identified. This study evaluated the safety, efficacy, and pharmacokinetics (PK) of SOF/velpatasvir (VEL) for 12 weeks in patients with HCV infection on dialysis.

Methods Treatment-naive or -experienced patients, of any genotype, with or without compensated cirrhosis undergoing hemodialysis or peritoneal dialysis, were enrolled to receive open-label SOF/VEL (400/100 mg) once daily for 12 weeks. The primary efficacy endpoint was a comparison of the SVR12 to a prespecified historic control rate of 83%. The primary safety endpoint was the proportion of patients who discontinued therapy due to adverse events (AEs). Secondary endpoints included safety, viral resistance and PK.

Results 59 patients were enrolled at 21 sites in Canada, United Kingdom, Spain, Israel, Australia and New Zealand. The median age was 62 years (range 49–86), 59% were male, 53% white, 32% treatment experienced, 29% had cirrhosis. Most patients had HCV genotype 1 (42%), or 3 (27%). Most (92%) were on hemodialysis with a mean dialysis duration of 7.3 years. Treatment was well tolerated; no one discontinued therapy due to AEs. One patient was discontinued therapy on day 74 for non-compliance with 48% study medication adherence by pill count. Overall, 56/59 (95%) of patients achieved SVR12. Two (3%) had virologic relapse (one with non-adherence). One patient did not achieve SVR12 due to death from suicide after SVR4. Exposures were consistent with the Phase 1 renal impairment study. The most frequent AEs were headache, fatigue, nausea, and vomiting. Serious AEs occurred in 19% of patients, none was assessed as related to study drug.

Conclusions Treatment with SOF/VEL for 12 weeks in patients with and without cirrhosis undergoing dialysis resulted in a 95% SVR12 rate. The regimen was safe and well-tolerated with no treatment-related discontinuations or treatment-related SAEs.